Page last updated: 2024-10-28

hexadecanesulfonyl fluoride and Huntington Disease

hexadecanesulfonyl fluoride has been researched along with Huntington Disease in 1 studies

AM 374: a palmitylsulfonyl fluoride; inhibits anandamide amidase; structure given in first source

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lastres-Becker, I1
de Miguel, R1
De Petrocellis, L1
Makriyannis, A1
Di Marzo, V1
Fernández-Ruiz, J1

Other Studies

1 other study available for hexadecanesulfonyl fluoride and Huntington Disease

ArticleYear
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
    Journal of neurochemistry, 2003, Volume: 84, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids, Neutral; Animals; Arachidonic Acids; Basal Ganglia; Can

2003